Drugs in Dev. Oncology
Undisclosed
France 
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,540.0 million
Deal Type : Licensing Agreement
Details : This agreement builds on Amunix’s previous technology assessment with Roche focused on using XTEN, a proprietary unstructured polypeptide, to extend drug half-life.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $40.0 million
October 01, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,540.0 million
Deal Type : Licensing Agreement
Lead Product(s) : K-NK002
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IND supports the Company’s planned NK-REALM Phase 1/2 study which will evaluate K-NK002 in 63 patients with blood cancer undergoing a haploidentical hematopoietic stem cell transplant (HSCT).
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 04, 2020
Lead Product(s) : K-NK002
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Kreos
Deal Size : $5.9 million
Deal Type : Financing
Kiadis Announces the Placement of €5 Million Convertible Bonds with Kreos
Details : The conversion of a sizeable portion of Kiadis's loan into a convertible structure supports its recent refocus on its proprietary K-NK platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $5.9 million
January 10, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Kreos
Deal Size : $5.9 million
Deal Type : Financing
Lead Product(s) : Iniparib
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2010
Lead Product(s) : Iniparib
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Centre François Baclesse | Centre Hospitalier Universitaire de Caen | Institut de cancérologie Strasbourg Europe | Centre Oscar Lambret
Deal Size : Inapplicable
Deal Type : Inapplicable
Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 13, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Centre François Baclesse | Centre Hospitalier Universitaire de Caen | Institut de cancérologie Strasbourg Europe | Centre Oscar Lambret
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Sanofi
Deal Size : $1,466.5 million
Deal Type : Expanded Collaboration
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
Details : Sanofi and Innate entered into a research collaboration and licensing agreement for the generation and evaluation of up to two bispecific NK cell engagers, using technology from Innate Pharma and Sanofi’s proprietary bispecific antibody format as well ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $26.6 million
December 19, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Sanofi
Deal Size : $1,466.5 million
Deal Type : Expanded Collaboration
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
Vorasidenib Expanded Access Program
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 25, 2022
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vaccinia virus Copenhagen Strain
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VVcopTK-RRis a large capacity Vaccinia virus Copenhagen strain genetically modified with the double deletion TK-RR- which restricts the viral replication to tumor cells only.
Product Name : VVcopTK-RR-
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 06, 2021
Lead Product(s) : Vaccinia virus Copenhagen Strain
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
177Lu-PSMA-617 Managed Access Program for mCRPC Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2021
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tedopi,Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : European Investment Bank
Deal Size : Undisclosed
Deal Type : Agreement
Details : This loan will help expand the clinical development of Tedopi® in combination with a checkpoint inhibitor in additional cancer indications.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
February 15, 2021
Lead Product(s) : Tedopi,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : European Investment Bank
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
